01 AI-Assisted Imaging Is Supporting More Precise Lesion Assessment During PCI The need for faster and more consistent lesion assessment is increasing the use of AI with intravascular ultrasound and optical coherence tomography during PCI. AI-assisted OCT software improved identification of calcium severity, vessel-preparation strategy, and stent diameter in a 2025 study of 30 interventional cardiologists, while reducing OCT assessment time by 0.5 minutes. This transition toward automated image interpretation supports more precise stent planning, reduces assessment variability, and can improve the integration of intravascular imaging into PCI workflows.
02 Robotic-Assisted PCI Is Moving Toward More Remote and Radiation-Sparing Procedures The need to reduce occupational radiation exposure and physical workload is shifting PCI from direct manual operation toward robotic-assisted systems controlled from radiation-shielded workstations. The 2026 PARTY randomized trial involving 148 patients found operator radiation exposure of 0.1 μSv with robotic PCI versus 13.6 μSv with manual PCI, while procedure time was not significantly longer. This transition toward robotic control can improve operator protection and workflow ergonomics while supporting more consistent device manipulation during interventional procedures.
01 Higher PCI Procedure Volumes and Cardiac Catheterization Lab Expansion Are Increasing Device Demand, Which Drives the Market. Higher PCI procedure volumes create greater demand for coronary stents, guidewires, catheters, balloons, and other devices used during cardiac interventions. A larger number of procedures increases procurement requirements across hospitals and cardiac centers, supporting steady device consumption. The outcome is higher sales volumes for interventional cardiology device manufacturers and suppliers. For example, hospitals performing large numbers of PCI procedures require regular supplies of drug-eluting stents, angioplasty balloons, and vascular access devices.Expansion of cardiac catheterization laboratories increases the number of facilities equipped to perform diagnostic and interventional cardiac procedures. Greater laboratory capacity creates additional demand for catheter-based devices, stents, guidewires, imaging accessories, and other procedure-related supplies. The outcome is broader procurement opportunities for manufacturers as hospitals establish or upgrade catheterization facilities. For example, newly equipped catheterization laboratories can support coronary angiography and PCI, creating recurring demand for consumable interventional devices.
01 Stringent Regulatory Requirements for Medical Devices and Limited Access to Specialized Cardiac Catheterization Facilities Restrain Market Expansion Stringent regulatory requirements can increase the time and cost required to introduce new interventional cardiology devices into the market. Clinical evidence, safety testing, quality standards, documentation, and regulatory approvals can extend product development and commercialization timelines. These compliance burdens can delay device launches, increase development costs, and slow the adoption of advanced interventional technologies.Limited access to specialized cardiac catheterization facilities can restrict the availability of interventional cardiology procedures, particularly in underserved regions. High infrastructure requirements, limited equipped hospitals, and uneven distribution of catheterization laboratories can constrain procedure capacity and patient access. These infrastructure gaps can reduce procedure volumes and limit the broader adoption of interventional cardiology devices.
01 Bioresorbable Scaffolds and Structural Heart Interventions Are Creating New Product Opportunities, Which Offers Growth Opportunities. Interventional cardiologists, hospitals, and medical device manufacturers represent key opportunities for next-generation coronary intervention products. Bioresorbable scaffolds can create new revenue through differentiated device portfolios, clinical partnerships, and premium product offerings. Companies such as Abbott and Biotronik have developed bioresorbable scaffold technologies.Hospitals, cardiac centers, and device manufacturers can address conditions such as aortic valve disease through transcatheter structural heart procedures. Broader procedure applications create revenue through specialized devices, catheter systems, procedure support, and associated services. Companies such as Edwards Lifesciences and Medtronic operate in structural heart intervention technologies.
01 Device Quality and Reliability Issues and Occupational Risks in Catheterization Laboratories Hinder Market Growth. Device failures, recalls, or performance problems can interrupt procedures and weaken clinician confidence in particular technologies. Real-life example: the FDA classified Boston Scientific's Imager II angiographic catheter issue as a Class I recall in September 2026 after two serious injuries were reported, illustrating how device-quality events can disrupt product use and market confidence.Repeated radiation exposure and other occupational hazards can make interventional cardiology demanding for clinical teams. The 2026 ANMCO position update highlights cumulative radiation exposure, musculoskeletal injuries, and psychological strain, which can increase workforce-management challenges for high-volume centers.
February 2026 Terumo Interventional Systems introduced next-generation guidewires and catheter technologies designed to improve navigation and performance during complex coronary interventions.
November 2025 Medtronic expanded its cardiac intervention portfolio with new catheter-based technologies and digital procedural support solutions. The expansion enhances treatment options for coronary and structural heart diseases.
September 2025 Boston Scientific launched advanced coronary intervention devices featuring enhanced deliverability and imaging integration for complex cardiovascular procedures. The products strengthen the company's interventional cardiology portfolio.
June 2025 Abbott expanded its structural heart and interventional cardiology portfolio by introducing next-generation imaging and catheter-based technologies for minimally invasive cardiovascular procedures. The innovations improve procedural precision and patient outcomes.